Atlas Trials

A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Clinical trial NCT05027139 · COMPLETED

Trial details

NCT number
NCT05027139
Sponsor
Jazz Pharmaceuticals
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
HER2-expressing Cancers
Start date
2021-09-15
Primary completion
2025-08-29
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.